At a glance
- Originator Eli Lilly and Company
- Class Anti-ischaemics; Neuroprotectants; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cerebral ischaemia
Most Recent Events
- 25 Jun 2001 No-Development-Reported for Cerebral ischaemia in USA (Unknown route)
- 30 Sep 1998 New profile
- 30 Sep 1998 Preclinical development for Cerebral ischaemia in USA (Unknown route)